Investment Thesis
Tyra Biosciences is a pre-commercial stage biotech company with no reported revenue, burning $95M annually in operating cash flow, and deteriorating losses (down 38.7% YoY). While the balance sheet shows adequate equity and liquidity, the company faces severe execution risk with less than one year of cash runway at current burn rates and absolute dependence on successful drug development and commercialization.
Strengths
- Strong balance sheet with $259.2M stockholders equity and minimal debt (0.00x D/E ratio)
- Adequate cash position of $77.4M with exceptional liquidity ratios (14.67x current ratio)
- No near-term debt obligations allowing flexibility for capital deployment
Risks
- No revenue generation indicates pre-commercial stage with significant development risk
- Operating losses expanding YoY (38.7% deterioration in net income), signaling worsening cash burn
- Cash runway of approximately 9-10 months at current $95.1M annual operating cash burn rate
- Requires successful Phase III trials, regulatory approval, and market adoption to achieve profitability
- Biotech dependency on single or limited drug pipeline with binary success/failure outcomes
Key Metrics to Watch
- Operating cash flow trend and runway extension through capital raises or cost reduction
- Clinical trial progress updates and regulatory milestones for lead drug candidates
- Quarterly cash burn rate and changes in cash reserves
- Patent expirations and competitive pipeline developments in target therapeutic areas
Financial Metrics
Revenue
N/A
Net Income
-119.9M
EPS (Diluted)
$-2.01
Free Cash Flow
-95.3M
Total Assets
282.6M
Cash
77.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-46.3%
ROA
-42.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
14.67x
Quick Ratio
14.67x
Debt/Equity
0.00x
Debt/Assets
8.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-18T01:51:22.343941 |
Data as of: 2025-12-31 |
Powered by Claude AI